PTO/SB/08B (07-06)
Approved for use through 09/30/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO	Complete if Known		
Substitute for form 1449IPTO	Application Number	10/630,587	
INFORMATION DISCLOSURE	Filing Date	07/29/2003	
STATEMENT BY APPLICANT	First Named Inventor	Kei Roger Aoki et al.	
	Art Unit	1656	
(Use as many sheets as necessary)	Examiner Name	Kam, Chih Min	
Sheet 1 of 1	Attorney Docket Number	17328-CON5(BOT)	

	NON PATENT LITERATURE DOCUMENTS	
Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	BORODIC G E et al., "Botulinum Toxin Therapy for Pain and Inflammatory Disorders: Mechanims and Therapeutic Effects", Expert Opinion on Investigational Drugs, Ashley Publications Ltd., London, GB, Vol. 8, No. 10, August 2001, pages 1531-1544	
	CUI M et al., "Botulinum Toxin Type A (BTX-A) Reduced Inflammatroy Pain in the Rat Formalin Model", Cephalaigia, Vol. 20, No. 4, May 2000, page 414 (Abstract)	
	·	
		No. the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. BORODIC G E et al., "Botulinum Toxin Therapy for Pain and Inflammatory Disorders: Mechanims and Therapeutic Effects", Expert Opinion on Investigational Drugs, Ashley Publications Ltd., London, GB, Vol. 8, No. 10, August 2001, pages 1531-1544 CUI M et al., "Botulinum Toxin Type A (BTX-A) Reduced Inflammatroy Pain in the Rat Formalin Model",

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer. U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.